SecBot SecBot

KROS drug pipeline

Keros Therapeutics, Inc. · 3 rated drugs
$10.03
−2.6% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
No history
No past FDA events with prices
IV rank
No data
No current options data
Rated drugs
3
1 mixed · 2 neutral
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
● neutral
Impact
PhasePhase 2
Time to marketUnknown — the drug is in Phase 2 for DMD with initial data expected H1 2027. If successful, Phase 3 trials and regulatory filing would follow, putting potential approval several years away (likely 2029-2031 at the earliest).

rinvatercept Updated Aug 27

What to watch

Watch for the Phase 2 DMD initial data readout for rinvatercept expected in H1 2027, and any regulatory engagement updates for the ALS program in H2 2026. The stock trades at ~$11.23 with analyst mean price target of ~$19.83 (69% upside), but the stock is 18.8% below its 200-day SMA, reflecting the pre-revenue, binary-risk profile typical of clinical-stage biotechs.

Bull case
  • Phase 1 data in healthy volunteers showed target engagement, favorable changes in muscle and bone mass, and a good safety profile, supporting advancement into two Phase 2 trials (DMD and ALS).
  • Keros has a strong balance sheet with $257.6M in cash providing runway into H1 2028, plus a $1.3B+ global licensing deal with Takeda for its other asset elritercept, which provides validation and potential milestone income.
  • Analyst consensus is bullish: 9 Buy/Strong Buy vs 0 Sell, with a mean price target of ~$19.83, roughly 69% above the current ~$11.23 price.
Bear case
  • Rinvatercept is still in early-stage development, Phase 1 only completed in healthy volunteers, with no efficacy data in patients yet. Phase 2 DMD data won't read out until H1 2027, leaving a long period with no near-term binary catalysts.
  • DMD and ALS are both notoriously difficult indications with high clinical trial failure rates. Multiple prior muscle-building approaches have failed in these diseases.
  • The stock trades 18.8% below its 200-day SMA ($13.84) and has a 52-week range of $9.69-$22.55, reflecting significant volatility and the binary-risk nature of clinical-stage biotech.
◆ mixed
Impact
PhasePhase 3 (MDS); Phase 3 planned (myelofibrosis)
Time to marketUnknown — several years: the Phase 3 ELRiSE MDS trial (elritercept vs epoetin alfa in low-risk MDS) only began dosing patients in July 2026, and the myelofibrosis Phase 3 is planned but not yet underway; no regulatory filing or PDUFA exists.

elritercept Updated Aug 2

What to watch

Watch KROS's Q2 2026 earnings (before market open, Aug 4, 2026) and any timing update on the 25% shareholder distribution of the $20M Takeda milestone. The next real value inflection, a Phase 3 readout, is years out, so near-term moves will be driven by Takeda milestones, financing/dilution news (no approved product; cash burn continuing), and execution on the ELRiSE MDS enrollment.

Bull case
  • Takeda validation is concrete: a $20M development milestone was triggered by first patient dosing in the Phase 3 ELRiSE MDS trial (8-K filed July 30, 2026), on top of a $200M upfront from the global license, evidence the partner judged Phase 2 data strong enough to fund a pivotal program.
  • Pipeline momentum: ELRiSE MDS is now enrolling and Takeda plans to advance elritercept into a Phase 3 myelofibrosis trial, per Q1 2026 company commentary.
  • Keros expects to distribute 25% of the net cash proceeds of the $20M milestone to stockholders, a tangible near-term capital return (8-K analysis).
Bear case
  • No near-term dated catalyst: the Phase 3 MDS readout is likely several years away, the myelofibrosis Phase 3 hasn't started, and there is no PDUFA, the stock has no imminent binary to re-rate on.
  • Pre-revenue and bleeding cash: Q1 2026 net loss of $23.7M (EPS -$1.21, a miss vs ~-$0.92 consensus) and revenue of just $367K, versus $211.2M in Q1 2025 that was one-time Takeda license income, a setup that can invite future dilution.
  • Full dependence on a partner: development and commercialization rest with Takeda, so timelines and milestone payments are outside Keros' control; the 8-K analysis itself flags Phase 3 failure risk and Takeda dependence.
● neutral
Impact
PhaseNonclinical / Preclinical
Time to marketKER-206 is at the nonclinical stage. Assuming successful IND-enabling studies, Phase 1 initiation would be at least 12-18 months away. Commercialization, if successful, would be many years away (likely 2030s).

KER-206 Updated Nov 7

What to watch

KER-206 is a preclinical asset with no near-term catalysts. The next meaningful update would likely come when Keros announces plans to file an IND or initiate first-in-human studies, which is probably 12+ months away. For KROS investors, the more immediate value drivers are the Phase 2 rinvatercept data in DMD expected in H1 2027 and Takeda's Phase 3 progress with elritercept.

Bull case
  • KER-206 showed reversal of bone loss in a mouse model of osteoporosis, suggesting potential as a novel anabolic (bone-building) therapy in a large market.
  • Keros has expertise in TGF-beta family ligand traps, having already advanced KER-050 (elritercept) into Phase 3 via a Takeda partnership and KER-065 (rinvatercept) into Phase 2.
  • The company has $259.5M in cash as of September 2026, providing runway into H2 2028 to advance KER-206 toward the clinic.
Bear case
  • KER-206 is at the nonclinical stage, meaning it has not yet entered human trials and faces a high probability of failure before ever reaching the clinic.
  • Osteoporosis is a highly competitive market with established therapies (bisphosphonates, denosumab, romosozumab) and many novel entrants, making differentiation difficult for an early-stage ligand trap.
  • Keros has no approved products and is burning cash (core operating loss of ~$27M in Q3 2026); KER-206 will require significant additional investment before generating any value.

Clinical trials

1 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
Dose A KER-012A Study to Investigate the Safety and Efficacy of KER-012 in Combination With Background Therapy in Adult Participants With Pulmonary Arterial Hypertension (PAH) (TROPOS Study).Phase 2Terminated · results113Mar 5, 2025